Methylation-Sensitive Cas9: A Revolutionary Gene-Editing Tool
The world of biotechnology and medicine has been revolutionized by CRISPR-Cas gene-editing tools, and the field continues to evolve with new iterations and improvements each year. A recent study has introduced a groundbreaking variant of the Cas9 protein, known as ThermoCas9, which selectively targets DNA based on its methylation state. This development has the potential to significantly impact our understanding of gene expression and tumor development.
Led by RNA structural biologist Hong Li from the Van Andel Institute, the research focused on ThermoCas9, a Cas9 variant isolated from the bacterium Geobacillus thermodenitrificans T12 in 2017. The discovery of methylation sensitivity in another Cas9 variant, AceCas9, prompted Li's team to investigate whether ThermoCas9 shared this unique property.
The key to ThermoCas9's methylation sensitivity lies in its interaction with DNA sequences. Both AceCas9 and ThermoCas9 are inhibited by methylation on cytosine residues within the protospacer adjacent motif (PAM). However, they bind to subtly different variants. AceCas9 is inhibited when methylated cytosine is followed by another cytosine (CpC), while ThermoCas9 is inhibited by CpC methylation and when methylated cytosine is followed by a guanine (CpG).
According to Rahul M. Kohli, a biochemist and epigeneticist at the University of Pennsylvania, the majority of methyl cytosine in mammalian genomes is found in a CpG context. This is because the reverse complement sequence on the opposing DNA strand is also a CpG sequence, allowing cellular machinery to maintain the methylation state. Li's group utilized cryo-electron microscopy to determine ThermoCas9's structure and its interaction with DNA sequences, revealing that methylation excludes ThermoCas9 from cutting or binding.
The implications of this discovery are profound. Methylation typically represses gene expression, and the loss of these marks can lead to tumor development. ThermoCas9's ability to selectively cut DNA in breast cancer cells with lost methylation at critical tumor genes while leaving healthy cells unaffected is a significant breakthrough. However, Li emphasizes that there is still much work to be done before this technology can be translated into a viable cancer therapy.
Beyond cancer, Kohli highlights the potential of ThermoCas9's methylation selectivity in studying basic biology. The idea of expanding beyond the traditional four bases of the genome to include methyl cytosine as a dynamic and interesting base is a game-changer. This innovation allows for the discrimination of the fifth state, opening up new possibilities in epigenetics research.
In conclusion, the discovery of ThermoCas9's methylation sensitivity is a significant advancement in gene-editing technology. It provides a deeper understanding of gene expression and tumor development, and its potential applications in basic biology research are vast. As the field continues to evolve, this breakthrough will undoubtedly shape the future of biotechnology and medicine.
